Search

#SyntheticDrugs
The New York Times @nytimes.com Β· New York City πŸ‡ΊπŸ‡Έ Β· 2d

Matt Richtel chronicles the experimental self-recovery journey of 27-year-old Rebecca, aka Becks, who, after struggling with addiction to various drugs including kratom, uses the untested synthetic compound SR-17018 in a desperate attempt to detox from her substance use, while grappling with both hopeful progress and the real risks of self-medication. #AddictionRecovery #SyntheticDrugs #MentalHealth #US #CN #IT

www.nytimes.com
Her Self-Experiment with Drug Detox Almost Broke Her
Matt Richtel spent a year following Becks's experimental recovery efforts, as part of a series of stories looking at the rise of ultrapotent lab-made drugs.
The New York Times @nytimes.com Β· New York City πŸ‡ΊπŸ‡Έ Β· 2d

Matt Richtel's article follows Rebecca, a 27-year-old woman who self-experimented with the unapproved synthetic drug SR-17018 in an attempt to overcome her addiction to kratom, detailing her hopes, struggles, and the broader implications of using novel psychoactive substances for recovery amidst the ongoing opioid crisis in the United States. #AddictionRecovery #SyntheticDrugs #MentalHealth #US #CN #IT

www.nytimes.com
Her Self-Experiment with Drug Detox Almost Broke Her
Matt Richtel spent a year following Becks's experimental recovery efforts, as part of a series of stories looking at the rise of ultrapotent lab-made drugs.
The New York Times @nytimes.com Β· New York City πŸ‡ΊπŸ‡Έ Β· 2d

Matt Richtel's article chronicles Rebecca "Becks," a 27-year-old woman engaged in self-experimentation with the untested synthetic drug SR-17018 in her quest for sobriety after struggling with addiction, amidst the backdrop of a rising overdose crisis in the U.S., highlighting both the desperate measures individuals take to overcome substance dependence and the inherent dangers of using unregulated substances. #AddictionRecovery #SyntheticDrugs #MentalHealthAwareness #US #CN #IT

www.nytimes.com
Her Self-Experiment with Drug Detox Almost Broke Her
Matt Richtel spent a year following Becks's experimental recovery efforts, as part of a series of stories looking at the rise of ultrapotent lab-made drugs.